Alyeska Investment Group
GNMX

Alyeska Investment Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Alyeska Investment Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100,000
Closed -$555K – 557
2016
Q2 		$555K Buy
+100,000
New +$525K 0.01% 400
2015
Q4 		– Sell
-78,575
Closed -$614K – 508
2015
Q3 		$614K Buy
78,575
+7,192
+10% +$55.8K 0.01% 416
2015
Q2 		$438K Buy
71,383
+1,155
+2% +$8.95K 0.01% 457
2015
Q1 		$566K Sell
70,228
-22,630
-24% -$171K 0.01% 465
2014
Q4 		$470K Buy
+92,858
New +$459K 0.01% 445

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Alyeska Investment Group's GNMX Position: Q3 2016 in Review

Alyeska Investment Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2016, closing a stake of 100,000 shares — an estimated $555K sold.

Alyeska Investment Group first reported a position in GNMX in Q4 2014 and held it in 5 quarters. The position peaked at $614K in Q3 2015. 68 funds tracked by Wall St. Rank hold GNMX as of Q3 2016.

  • Alyeska Investment Group reported no remaining Aevi Genomic Medicine Inc position as of Q3 2016 after selling out during the quarter.
  • Alyeska Investment Group sold 100,000 Aevi Genomic Medicine Inc shares in Q3 2016, an estimated $555K.
  • Alyeska Investment Group first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 5 quarters.
  • Alyeska Investment Group's Aevi Genomic Medicine Inc position peaked at $614K in Q3 2015.
  • 68 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2016.

Based on Alyeska Investment Group's 13F filing for Q3 2016, filed 14 Nov 2016.